FY2024 EPS Estimates for 2seventy bio Lowered by Analyst

2seventy bio, Inc. (NASDAQ:TSVT - Free Report) - Stock analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for 2seventy bio in a research report issued to clients and investors on Wednesday, December 4th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($1.45) for the year, down from their previous estimate of ($1.13). The consensus estimate for 2seventy bio's current full-year earnings is ($1.46) per share. Leerink Partnrs also issued estimates for 2seventy bio's Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.09) EPS, FY2026 earnings at $0.12 EPS, FY2027 earnings at $0.53 EPS and FY2028 earnings at $0.66 EPS.

2seventy bio Trading Up 3.5 %

Shares of 2seventy bio stock traded up $0.12 on Friday, hitting $3.53. 142,111 shares of the company traded hands, compared to its average volume of 315,487. The business has a 50-day simple moving average of $4.39 and a 200 day simple moving average of $4.38. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $6.40.

Institutional Investors Weigh In On 2seventy bio

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its stake in 2seventy bio by 11.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 28,929 shares of the company's stock valued at $155,000 after purchasing an additional 2,893 shares in the last quarter. Nisa Investment Advisors LLC bought a new position in shares of 2seventy bio in the 2nd quarter valued at about $52,000. Bank of New York Mellon Corp grew its position in 2seventy bio by 5.4% in the second quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company's stock worth $758,000 after acquiring an additional 10,077 shares in the last quarter. BBR Partners LLC increased its stake in 2seventy bio by 66.7% during the second quarter. BBR Partners LLC now owns 25,000 shares of the company's stock worth $96,000 after acquiring an additional 10,000 shares during the last quarter. Finally, American Century Companies Inc. raised its position in 2seventy bio by 16.6% during the second quarter. American Century Companies Inc. now owns 79,953 shares of the company's stock valued at $308,000 after purchasing an additional 11,363 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.